Defining the Role of Icosapent Ethyl in Clinical Practice. [Review]
Defining the Role of Icosapent Ethyl in Clinical Practice. [Review]
- 2020
Available online from MWHC library: 2001 - 2009
The health benefit of fish oil, i.e. omega-3 fatty acids (omega-3 FA) has a long history of debate. While there are a number of medications to reduce serum triglyceride levels, none have shown unanimous cardiovascular (CV) benefits. The most recent Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) assessing the CV outcome of one highly purified prescription omega-3 FA has certainly rejuvenated the debate. While this trial has been regarded as one of the most important landmark trials in preventive cardiology, the tolerability issue in a very high dose (4 g/day, as administered in the trial) is still a matter of concern. This article summarizes the current status and future perspective of icosapent ethyl in clinical practice in light of REDUCE-IT.
English
1175-3277
10.1007/s40256-020-00402-4 [doi] 10.1007/s40256-020-00402-4 [pii]
*Eicosapentaenoic Acid/aa [Analogs & Derivatives]
*Hypertriglyceridemia/dt [Drug Therapy]
Drug Dosage Calculations
Eicosapentaenoic Acid/ad [Administration & Dosage]
Eicosapentaenoic Acid/ae [Adverse Effects]
Eicosapentaenoic Acid/tu [Therapeutic Use]
Humans
Randomized Controlled Trials as Topic
Risk Factors
MedStar Union Memorial Hospital
Journal Article
Available online from MWHC library: 2001 - 2009
The health benefit of fish oil, i.e. omega-3 fatty acids (omega-3 FA) has a long history of debate. While there are a number of medications to reduce serum triglyceride levels, none have shown unanimous cardiovascular (CV) benefits. The most recent Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) assessing the CV outcome of one highly purified prescription omega-3 FA has certainly rejuvenated the debate. While this trial has been regarded as one of the most important landmark trials in preventive cardiology, the tolerability issue in a very high dose (4 g/day, as administered in the trial) is still a matter of concern. This article summarizes the current status and future perspective of icosapent ethyl in clinical practice in light of REDUCE-IT.
English
1175-3277
10.1007/s40256-020-00402-4 [doi] 10.1007/s40256-020-00402-4 [pii]
*Eicosapentaenoic Acid/aa [Analogs & Derivatives]
*Hypertriglyceridemia/dt [Drug Therapy]
Drug Dosage Calculations
Eicosapentaenoic Acid/ad [Administration & Dosage]
Eicosapentaenoic Acid/ae [Adverse Effects]
Eicosapentaenoic Acid/tu [Therapeutic Use]
Humans
Randomized Controlled Trials as Topic
Risk Factors
MedStar Union Memorial Hospital
Journal Article